Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06510426
PHASE2

Early Interferon-beta Treatment for West-Nile Virus Infection

Sponsor: Tel-Aviv Sourasky Medical Center

View on ClinicalTrials.gov

Summary

West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease. The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-07-14

Completion Date

2025-12-31

Last Updated

2024-07-23

Healthy Volunteers

No

Interventions

DRUG

Rebif 44 MCG Per 0.5 ML Prefilled Syringe

Rebif 44mcg per 0.5ml administered subcutaneously

DRUG

Saline

0.5mL of saline administered subcutaneously

Locations (1)

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel